CN100579533C - 治疗疼痛的化合物 - Google Patents

治疗疼痛的化合物 Download PDF

Info

Publication number
CN100579533C
CN100579533C CN200480004454A CN200480004454A CN100579533C CN 100579533 C CN100579533 C CN 100579533C CN 200480004454 A CN200480004454 A CN 200480004454A CN 200480004454 A CN200480004454 A CN 200480004454A CN 100579533 C CN100579533 C CN 100579533C
Authority
CN
China
Prior art keywords
pain
purposes
chemical compound
inflammatory
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200480004454A
Other languages
English (en)
Chinese (zh)
Other versions
CN1750835A (zh
Inventor
P·理查森
K·李
L·莱昂纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cbt Development Ltd
Offen Beal Witt Rom Open Corp Sweden
Swedish Orphan Biovitrum AB
Original Assignee
Cambridge Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Biotechnology Ltd filed Critical Cambridge Biotechnology Ltd
Publication of CN1750835A publication Critical patent/CN1750835A/zh
Application granted granted Critical
Publication of CN100579533C publication Critical patent/CN100579533C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
CN200480004454A 2003-03-07 2004-03-05 治疗疼痛的化合物 Expired - Fee Related CN100579533C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0305149.7A GB0305149D0 (en) 2003-03-07 2003-03-07 Compounds for the treatment of pain
GB0305149.7 2003-03-07

Publications (2)

Publication Number Publication Date
CN1750835A CN1750835A (zh) 2006-03-22
CN100579533C true CN100579533C (zh) 2010-01-13

Family

ID=9954247

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200480004454A Expired - Fee Related CN100579533C (zh) 2003-03-07 2004-03-05 治疗疼痛的化合物

Country Status (19)

Country Link
US (1) US7759321B2 (enExample)
EP (1) EP1603577B1 (enExample)
JP (1) JP2006519823A (enExample)
KR (1) KR20050115273A (enExample)
CN (1) CN100579533C (enExample)
AT (1) ATE401087T1 (enExample)
AU (1) AU2004216889B2 (enExample)
CA (1) CA2514098A1 (enExample)
CY (1) CY1108416T1 (enExample)
DE (1) DE602004015085D1 (enExample)
DK (1) DK1603577T3 (enExample)
ES (1) ES2310288T3 (enExample)
GB (1) GB0305149D0 (enExample)
NO (1) NO20054476L (enExample)
NZ (1) NZ541521A (enExample)
PL (1) PL1603577T3 (enExample)
PT (1) PT1603577E (enExample)
SI (1) SI1603577T1 (enExample)
WO (1) WO2004078183A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305153D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
GB0305150D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
WO2005084653A2 (en) * 2004-03-05 2005-09-15 Cambridge Biotechnology Limited Adenosine receptor agonists
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8399400B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CN1947717B (zh) * 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
EP2081932A2 (en) 2006-06-27 2009-07-29 BIOVITRUM AB (publ) 2-o'-methyladenosine derivatives and their use as agonists or antagonists of an adenosine receptor
CA2657973A1 (en) 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Therapeutic compounds
JP2009541438A (ja) * 2006-06-27 2009-11-26 ビオヴィトルム・アクチボラゲット（プブリクト） 治療用化合物
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
CN103342727A (zh) * 2013-07-01 2013-10-09 淮海工学院 一种2-甲氧基腺苷的合成方法
JP6440240B2 (ja) * 2014-02-19 2018-12-19 国立大学法人富山大学 末梢神経障害誘発感覚異常を改善する外用剤
AU2020320115A1 (en) * 2019-07-31 2022-02-24 Sea4Us - Biotecnologia E Recursos Marinhos, Lda. Nitenin analogue compounds and their use in the treatment of chronic and acute pain

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2258378A1 (de) * 1971-12-01 1973-06-14 Takeda Chemical Industries Ltd Adenosinderivate, ihre herstellung und verwendung
CN1147815A (zh) * 1994-05-10 1997-04-16 山道士有限公司 腺苷衍生物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4861498A (enExample) 1971-12-01 1973-08-28
DE2359536C2 (de) 1972-12-08 1984-08-02 Takeda Chemical Industries, Ltd., Osaka 2,6-Diaminonebularinderivate
JPS5461195A (en) 1977-10-21 1979-05-17 Takeda Chem Ind Ltd N2-substituted phenyl-2,6-diaminonebularin
JPS5461194A (en) 1977-10-21 1979-05-17 Takeda Chem Ind Ltd Preparation of n22substituted 2*66diaminonebularin
US4705758A (en) 1984-06-19 1987-11-10 Warner-Lambert Company Adenosine receptor assay and kit
US5677290A (en) * 1990-05-10 1997-10-14 Fukunaga; Atsuo F. Therapeutic use of adenosine compounds as surgical anesthetics
US5679650A (en) * 1993-11-24 1997-10-21 Fukunaga; Atsuo F. Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US5683989A (en) * 1993-12-17 1997-11-04 Novo Nordisk A/S Treatment of ischemias by administration of 2,N6 -substituted adenosines
US5877180A (en) 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
IT1275420B (it) 1995-06-02 1997-08-05 Schering Plough S P A Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261
EP1044004A1 (en) 1998-01-08 2000-10-18 The University Of Virginia Patent Foundation A2a adenosine receptor agonists in combination with a type iv phosphodiesterase inhibitors
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305153D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2258378A1 (de) * 1971-12-01 1973-06-14 Takeda Chemical Industries Ltd Adenosinderivate, ihre herstellung und verwendung
CN1147815A (zh) * 1994-05-10 1997-04-16 山道士有限公司 腺苷衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
2-Alkoxyadenosines:Potent and selective agonists atthe coronary artery A2 adenosine receptor. UEEDA M ET AL.JOURNAL OF MEDICINAL CHEMISTRY,AMERICAN CHEMICAL SOCIETY.WASHINGTON,US.,Vol.34 . 1991
2-Alkoxyadenosines:Potent and selective agonists atthe coronary artery A2 adenosine receptor. UEEDA M ET AL.JOURNAL OF MEDICINAL CHEMISTRY,AMERICAN CHEMICAL SOCIETY.WASHINGTON,US.,Vol.34 . 1991 *

Also Published As

Publication number Publication date
NO20054476D0 (no) 2005-09-27
EP1603577B1 (en) 2008-07-16
US20070066559A1 (en) 2007-03-22
WO2004078183A1 (en) 2004-09-16
DE602004015085D1 (de) 2008-08-28
US7759321B2 (en) 2010-07-20
DK1603577T3 (da) 2008-11-17
AU2004216889B2 (en) 2009-06-11
PL1603577T3 (pl) 2009-01-30
KR20050115273A (ko) 2005-12-07
GB0305149D0 (en) 2003-04-09
JP2006519823A (ja) 2006-08-31
HK1087629A1 (zh) 2006-10-20
PT1603577E (pt) 2008-10-23
NZ541521A (en) 2008-09-26
NO20054476L (no) 2005-11-24
AU2004216889A1 (en) 2004-09-16
ES2310288T3 (es) 2009-01-01
CA2514098A1 (en) 2004-09-16
EP1603577A1 (en) 2005-12-14
SI1603577T1 (sl) 2008-12-31
CY1108416T1 (el) 2013-09-04
CN1750835A (zh) 2006-03-22
ATE401087T1 (de) 2008-08-15

Similar Documents

Publication Publication Date Title
CN100579533C (zh) 治疗疼痛的化合物
CN100471503C (zh) 海绵核苷（2-甲氧腺苷）在制备治疗疼痛的药物中的用途
JP4701330B2 (ja) 治療用化合物の同定
US11447778B2 (en) TNF-targeting aptamers and uses thereof for treatment or diagnosing TNF-related inflammatory diseases
EP2735316A1 (en) New therapeutic approaches for treating neuroinflammatory conditions
HK1087629B (en) Compounds for the treatment of pain
HK1086186B (en) Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
HK1125031A (en) Use of spongosine as an analgesic
US20230055568A1 (en) Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome
US20060094709A1 (en) Methods for the treatment of bipolar disorder using carbamazepine
US20050124601A1 (en) Methods for the treatment of bipolar disorder using carbamazepine
US20060293218A1 (en) Salicylate therapeutic compound and process for controlled delivery thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1087629

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1087629

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: CBT DEVELOPMENT CO., LTD.

Free format text: FORMER OWNER: SWEDEN OFFENBI OVERSTROM PUBLIC CO., LTD.

Effective date: 20110228

Owner name: BIOVITRUM AB

Free format text: FORMER OWNER: CAMBRIDGE BIOTECHNOLOGY LTD.

Effective date: 20110228

Owner name: SWEDEN OFFENBI OVERSTROM PUBLIC CO., LTD.

Free format text: FORMER OWNER: BIOVITRUM AB

Effective date: 20110228

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: CAMBRIDGE, UK TO: STOCKHOLM, SWEDEN

Free format text: CORRECT: ADDRESS; FROM: STOCKHOLM, SWEDEN TO: SWEDEN STOCKHOLM

Free format text: CORRECT: ADDRESS; FROM: SWEDEN STOCKHOLM TO: LONDON, UK

TR01 Transfer of patent right

Effective date of registration: 20110228

Address after: London, England

Patentee after: CBT DEVELOPMENT LTD.

Address before: Stockholm, Sweden

Patentee before: Offen Beal Witt Rom open Corporation, Sweden

Effective date of registration: 20110228

Address after: Stockholm, Sweden

Patentee after: Offen Beal Witt Rom open Corporation, Sweden

Address before: Stockholm

Patentee before: Biovitrum AB

Effective date of registration: 20110228

Address after: Stockholm

Patentee after: BIOVITRUM AB

Address before: cambridge

Patentee before: Cambridge Biotechnology Ltd.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100113

Termination date: 20110305